Incorporation of TILs in daily breast cancer care: how much evidence can we bear?
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incorporation of TILs in daily breast cancer care: how much evidence can we bear?
Authors
Keywords
-
Journal
VIRCHOWS ARCHIV
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-19
DOI
10.1007/s00428-022-03276-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer
- (2021) Lauren C. Brown et al. CANCER JOURNAL
- Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
- (2021) Leisha A Emens et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
- (2021) Eric P Winer et al. LANCET ONCOLOGY
- Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease
- (2021) Sanaz Samiei et al. JAMA Surgery
- PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays
- (2021) Anne Grabenstetter et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
- (2021) D. Miles et al. ANNALS OF ONCOLOGY
- Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers
- (2021) Peter Savas et al. BREAST CANCER RESEARCH AND TREATMENT
- Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer
- (2021) Darren Kilmartin et al. Cancers
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
- (2021) Khalid El Bairi et al. npj Breast Cancer
- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- The 2019 WHO classification of tumours of the breast
- (2020) Puay Hoon Tan et al. HISTOPATHOLOGY
- The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers into breast cancer clinical trials and daily practice
- (2020) Paula I Gonzalez‐Ericsson et al. JOURNAL OF PATHOLOGY
- MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial
- (2020) A. Jo Chien et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
- (2020) Emily S. Reisenbichler et al. MODERN PATHOLOGY
- Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
- (2020) Jin Sun Lee et al. Cancers
- Neo‐adjuvant therapy for triple‐negative breast cancer: Insights from a network meta‐analysis
- (2020) Hirotaka Miyashita et al. Breast Journal
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
- (2020) Jan Hudeček et al. npj Breast Cancer
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
- (2020) Zuzana Kos et al. npj Breast Cancer
- 159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group
- (2020) V.M.T. De Jong et al. ANNALS OF ONCOLOGY
- Association of Pathological Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-analysis
- (2020) Min Huang et al. CANCER RESEARCH
- A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 (PD‐L1) immunohistochemistry assays for scoring in triple‐negative breast cancer
- (2020) Aurelia Noske et al. HISTOPATHOLOGY
- How current assay approval policies are leading to unintended imprecision medicine
- (2020) Roberto Salgado et al. LANCET ONCOLOGY
- Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
- (2020) Torsten O Nielsen et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer
- (2019) Rim S Kim et al. JNCI-Journal of the National Cancer Institute
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) F Cardoso et al. ANNALS OF ONCOLOGY
- Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray
- (2019) Sandra Martinez-Morilla et al. LABORATORY INVESTIGATION
- “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
- (2019) Emina Torlakovic et al. MODERN PATHOLOGY
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
- (2019) H J Burstein et al. ANNALS OF ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy
- (2019) D. Elias et al. ONCOGENE
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
- (2019) J H Park et al. ANNALS OF ONCOLOGY
- Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study
- (2018) Mark O’Loughlin et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
- (2018) F. Klauschen et al. SEMINARS IN CANCER BIOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer
- (2017) Reinhard Büttner et al. JOURNAL OF CLINICAL ONCOLOGY
- Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer
- (2017) Andreas Heindl et al. JNCI-Journal of the National Cancer Institute
- Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
- (2017) Maria Vittoria Dieci et al. SEMINARS IN CANCER BIOLOGY
- Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer
- (2017) Andreas Heindl et al. JNCI-Journal of the National Cancer Institute
- Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group
- (2016) Shannon K. Swisher et al. ANNALS OF SURGICAL ONCOLOGY
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Lyndsay N. Harris et al. JOURNAL OF CLINICAL ONCOLOGY
- Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
- (2016) Carsten Denkert et al. MODERN PATHOLOGY
- Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer
- (2015) Sidra Nawaz et al. MODERN PATHOLOGY
- An international study to increase concordance in Ki67 scoring
- (2015) Mei-Yin C Polley et al. MODERN PATHOLOGY
- Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group
- (2015) Elena Provenzano et al. MODERN PATHOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- (2009) R. M. Simon et al. JNCI-Journal of the National Cancer Institute
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now